The current data imply that a modest level of TNFα modulation, using an orally bioavailable small molecule, is effective in preventing cognitive decline and reducing PHF tau and insoluble amyloid pathology while not impairing the central or peripheral immune system or inducing other adverse effects. Here, MAPT is linked to Mental deterioration.